{"log_id": 1674078056126313626, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 0.000734, "average": 0.986965, "min": 0.901285}, "location": {"width": 701, "top": 143, "height": 34, "left": 152}, "words": "量80mg/d时血浆暴露量40~51倍),可见幼仔出生死亡率增加、体重降低"}, {"probability": {"variance": 0.000548, "average": 0.992348, "min": 0.851016}, "location": {"width": 810, "top": 180, "height": 37, "left": 193}, "words": "致癌性:F344大鼠和B6C3F1小鼠为期两年的致癌试验中,雄性大鼠和雌性小鼠分别"}, {"probability": {"variance": 0.000599, "average": 0.984184, "min": 0.899882}, "location": {"width": 850, "top": 218, "height": 39, "left": 152}, "words": "在剂量为24mgkg(约为人用剂量80mg/d时的血浆暴露量的25倍)和18.75mg/kg(约为人"}, {"probability": {"variance": 0.000745, "average": 0.98969, "min": 0.855168}, "location": {"width": 850, "top": 254, "height": 38, "left": 151}, "words": "用剂量80mg/d时的血浆暴露量的12.5倍)时可见移行细胞乳头状瘤和膀胱癌。膀胱癌是肾"}, {"probability": {"variance": 1e-06, "average": 0.998567, "min": 0.996697}, "location": {"width": 219, "top": 294, "height": 25, "left": 151}, "words": "脏和膀胱结石所继发的"}, {"probability": {"variance": 4e-06, "average": 0.998244, "min": 0.993763}, "location": {"width": 133, "top": 331, "height": 25, "left": 158}, "words": "【药代动力学】"}, {"probability": {"variance": 3e-06, "average": 0.998281, "min": 0.995709}, "location": {"width": 156, "top": 367, "height": 26, "left": 192}, "words": "据国外文献报道"}, {"probability": {"variance": 4.5e-05, "average": 0.995676, "min": 0.971986}, "location": {"width": 809, "top": 402, "height": 36, "left": 191}, "words": "在健康受试者中,10~120mg剂量范围内,单次和多次给药非布司他的最大血浆浓"}, {"probability": {"variance": 0.001144, "average": 0.988194, "min": 0.794874}, "location": {"width": 853, "top": 440, "height": 37, "left": 150}, "words": "度(Cmax)和AUC呈剂量相关性增加。每24小时给予治疗剂量时,体内无蓄积。非布司他"}, {"probability": {"variance": 0.016416, "average": 0.965089, "min": 0.408988}, "location": {"width": 852, "top": 476, "height": 35, "left": 148}, "words": "的终末消除半衰期(t)约为5~8小时。通过群体药代动力学分析,非布司他在痛风的高"}, {"probability": {"variance": 1e-06, "average": 0.999131, "min": 0.996356}, "location": {"width": 496, "top": 514, "height": 29, "left": 149}, "words": "尿酸血症患者中的药代动力学参数与健康受试者相似"}, {"probability": {"variance": 4.4e-05, "average": 0.997791, "min": 0.958626}, "location": {"width": 808, "top": 551, "height": 34, "left": 190}, "words": "吸收:口服给药后,放射性标记的非布司他的吸收率至少为49%(根据尿液中总回收"}, {"probability": {"variance": 0.000239, "average": 0.993513, "min": 0.903388}, "location": {"width": 851, "top": 586, "height": 39, "left": 148}, "words": "的放射性标记物)。服药后1~1.5小时能达到最大血浆浓度。多次口服非布司他40mg/d"}, {"probability": {"variance": 0.006482, "average": 0.960432, "min": 0.641925}, "location": {"width": 851, "top": 624, "height": 36, "left": 147}, "words": "或80mg/d,Cmx分别是1.6±0.6μg/mL(N=30)2.6±1.7μg/mL(N=227)。还未进行"}, {"probability": {"variance": 4.7e-05, "average": 0.996039, "min": 0.972251}, "location": {"width": 326, "top": 662, "height": 26, "left": 148}, "words": "非布司他片的绝对生物利用度研究"}, {"probability": {"variance": 0.003503, "average": 0.979432, "min": 0.611522}, "location": {"width": 806, "top": 696, "height": 39, "left": 189}, "words": "服用非布司他80mg/d并同时进食高脂肪餐,多次给药后Cmax降低49%,AUC降低"}, {"probability": {"variance": 0.001228, "average": 0.987205, "min": 0.775308}, "location": {"width": 845, "top": 733, "height": 40, "left": 149}, "words": "8%。然而,血清尿酸浓度降低无临床意义(进餐后58%,空腹51%)。因此,非布司他"}, {"probability": {"variance": 8e-05, "average": 0.995682, "min": 0.969134}, "location": {"width": 224, "top": 773, "height": 27, "left": 144}, "words": "给药无需考虑食物因素"}, {"probability": {"variance": 3.3e-05, "average": 0.996038, "min": 0.974267}, "location": {"width": 808, "top": 808, "height": 38, "left": 186}, "words": "单剂量给予80mg非布司他合并抗酸剂(包括氢氧化镁、氢氧化铝)的试验提示非布"}, {"probability": {"variance": 0.003779, "average": 0.977057, "min": 0.618625}, "location": {"width": 849, "top": 845, "height": 38, "left": 145}, "words": "司他吸收延迟(约1小时),Cmax降低31%、AUC降低15%。相对于Cmax,AUC与药效"}, {"probability": {"variance": 1.9e-05, "average": 0.996637, "min": 0.983085}, "location": {"width": 851, "top": 882, "height": 38, "left": 143}, "words": "更有相关性,但AUC的改变无显著的临床意义。因此,非布司他给药无需考虑抗酸剂因"}, {"probability": {"variance": 0, "average": 0.999324, "min": 0.999324}, "location": {"width": 25, "top": 921, "height": 25, "left": 144}, "words": "素"}, {"probability": {"variance": 0.011113, "average": 0.965158, "min": 0.395918}, "location": {"width": 810, "top": 955, "height": 37, "left": 184}, "words": "分布:非布司他平均表观稳态分布容积( VSS/F)大约是50L(CV约40%)。血浆蛋"}, {"probability": {"variance": 0.004489, "average": 0.986591, "min": 0.553554}, "location": {"width": 829, "top": 992, "height": 37, "left": 144}, "words": "白结合率约99.2%主要和血清白蛋白结合),40mg和80mg剂量的血浆蛋白结合率不变"}, {"probability": {"variance": 0.000873, "average": 0.988223, "min": 0.831688}, "location": {"width": 809, "top": 1028, "height": 38, "left": 185}, "words": "代谢:非布司他被广泛代谢,通过与尿苷二磷酸葡萄糖苷酸转移酶(UGT)结合,通"}, {"probability": {"variance": 0.016627, "average": 0.947026, "min": 0.458542}, "location": {"width": 830, "top": 1066, "height": 37, "left": 141}, "words": "过细胞色素P450(CYP)系统、非P450酶系统进行氧化。UGT包括UGT1AI、UGT1A3"}, {"probability": {"variance": 0.004222, "average": 0.976609, "min": 0.573408}, "location": {"width": 846, "top": 1105, "height": 35, "left": 145}, "words": "UGT1A9和UGT2B7,CYP包括CYP1A2、2C8和2C9。每种酶在非布司他代谢中作用的大"}, {"probability": {"variance": 1.9e-05, "average": 0.997544, "min": 0.981113}, "location": {"width": 852, "top": 1140, "height": 39, "left": 142}, "words": "小均不明确。异丁基侧链氧化生成了4种具有药理学活性的羟基代谢产物但其在血浆中"}, {"probability": {"variance": 1.1e-05, "average": 0.99723, "min": 0.988108}, "location": {"width": 260, "top": 1182, "height": 27, "left": 142}, "words": "的浓度比非布司他要低的多"}, {"probability": {"variance": 0.000476, "average": 0.989991, "min": 0.887043}, "location": {"width": 806, "top": 1216, "height": 38, "left": 183}, "words": "尿液与粪便检测结果显示,非布司他体内主要代谢产物有:非布司他酰基葡萄糖醛酸"}, {"probability": {"variance": 0.0046, "average": 0.979305, "min": 0.589574}, "location": {"width": 848, "top": 1252, "height": 39, "left": 141}, "words": "苷代谢产物(约剂量的35%)和氧化代谢产物67M-1(约剂量的10%)、67M-2(约剂量的"}, {"probability": {"variance": 0.0052, "average": 0.977348, "min": 0.589476}, "location": {"width": 762, "top": 1291, "height": 35, "left": 140}, "words": "11%)和67M-4(约剂量的14%),其中67M-4是由67M-1代谢的二次代谢产物"}, {"probability": {"variance": 0.003986, "average": 0.974936, "min": 0.742512}, "location": {"width": 806, "top": 1327, "height": 38, "left": 182}, "words": "消除:非布司他通过肝脏和肾脏途径进行消除。口服C标记的非布司他80mg,约"}, {"probability": {"variance": 0.000191, "average": 0.993182, "min": 0.922558}, "location": {"width": 849, "top": 1365, "height": 37, "left": 141}, "words": "49%通过尿液排泄,包括非布司他原型(3%)、酰基葡萄糖醛酸苷代谢产物(30%)、已知"}, {"probability": {"variance": 0.00044, "average": 0.990528, "min": 0.888577}, "location": {"width": 828, "top": 1403, "height": 37, "left": 141}, "words": "的氧化代谢产物及其结合物(13%)、其他未知的代谢产物(3%)。除了通过尿液排泄"}, {"probability": {"variance": 0.000122, "average": 0.994477, "min": 0.947287}, "location": {"width": 821, "top": 1442, "height": 36, "left": 138}, "words": "大约45%通过粪便排泄,包括非布司他原型(12%)、酰基葡萄糖醛酸苷代谢产物(1%)"}, {"probability": {"variance": 3.9e-05, "average": 0.996243, "min": 0.97591}, "location": {"width": 654, "top": 1481, "height": 33, "left": 140}, "words": "已知的氧化代谢产物及其结合物(25%)、其他未知的代谢产物(7%"}, {"probability": {"variance": 3.2e-05, "average": 0.995967, "min": 0.979872}, "location": {"width": 445, "top": 1520, "height": 29, "left": 178}, "words": "非布司他平均终末消除半衰期大约为5~8小时"}, {"probability": {"variance": 4e-06, "average": 0.9979, "min": 0.995688}, "location": {"width": 89, "top": 1559, "height": 25, "left": 180}, "words": "特殊人群"}], "language": 3}